Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis
NCT02171104Phase 2Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2014
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cells in inherited metabolic disorders (IMD), osteopetrosis, sponsored by Masonic Cancer Center. Started Jul 2014; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
inherited metabolic disorders (IMD)osteopetrosis
Beyond the preview
Go deeper on NCT02171104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171104.